|
|
||||||||
Published online before print October 21, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

* Departments of Pathology and NYU Cancer Institute and
Cell Biology, New York University School of Medicine, New York
2 Correspondence: New York University School of Medicine, Department of Pathology, Room 538 MSB, 550 First Avenue, New York, NY 10016. E-mail: tsiagv01{at}med.nyu.edu
Systemic injection of small amounts of transforming growth factor-ß (TGF-ß), a cytokine produced by lymphoid and other cells, has a profound effect in protecting mice from the inflammatory demyelinating lesions of experimental allergic encephalomyelitis (EAE; an animal model for multiple sclerosis). However, TGF-ß has side-effects, which might be avoided if the cells producing TGF-ß can be delivered to the affected site in the nervous system to insure its local release in small amounts. Myelin basic protein (MBP)-specific, cloned CD4+ T cells were engineered by retroviral transduction to produce latent TGF-ß. Studies about the spontaneous form of EAE in T cell receptor (TCR)-transgenic recombination-activating gene (RAG)-1/ mice showed that essentially all of the MBP-specific, TCR-transgenic RAG-1/ (BALB/cxB10.PL)F1 mice develop spontaneous EAE by the age of 11 weeks. By 12 weeks, 2550% of the mice have died from disease. A single injection of TGF-ß1-transduced T helper cell type 1 (Th1) cells significantly protected the mice from EAE, and untransduced Th1 cells did not protect. MBP-specific BALB/c Th2 clones, transduced with TGF-ß1-internal ribosome entry site-green fluorescent protein (GFP) significantly reduced EAE induction by untransduced Th1 cells in RAG-1/ B10.PL mice. Furthermore, the GFP+ TGF-ß1-producing Th2 cells were detectable in the spinal cords of the injected mice.
Key Words: cytokines gene therapy multiple sclerosis
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |